1 Bericht in Erfüllung der Postulate 12.3100 Kessler, 12.3124 Gilli und 12.3207 Steiert. Bern, 24. Juni 2015. unter:
www.bag.admin.ch/.../patientenrechte_partizipation_bericht_DE.pdf
2 OR 394ff.
3 Hardy Landolt, Iris Herzog-Zwitter. Arzthaftungsrecht, S. 1.
4 Hallermann 1959, in: Cordt von Brandis/Otto Pribilla: Arzt und Kunstfehlervorwurf, S. 9. 1973.
5 Klotz L, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015 Jan 20;33(3):272–7.
doi: 10.1200/JCO.2014.55.1192. Epub 2014 Dec 15.
6 New York Times, 6. Oktober 1999.
7 New York Times, 14. November 2014.
8 Die Welt, 20. Februar 2014.
10 Ross HM, et al. Do adenocarcinomas of the prostate with Gleason score (GS) </=6 have the potential to metastasize to lymph nodes? The American journal of surgical pathology. 2012;36:1346–52.
11 Schroder FH, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384:2027–35.
12 Mühlhauser I, Höldke B. Information zum Mammographiescreening – vom Trugschluss zur Ent-Täuschung. Radiologe. 2002;42:299–304.
13 Schwartz, et al. Enthusiasm for cancer screening in the United States.JAMA. 2004 Jan 7;291(1):71–8.
16 Randazzo M, et al. A «PSA pyramid» for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening. Eur Urol. 2015 Oct;68(4):591–7.
doi: 10.1016/j.eururo.2014.04.005. Epub 2014 Apr 18.
17 Börgermann C, et al. PSA quo vadis? It is reasonable to start with prostate-specific antigen testing at the age of 40! Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1190–5.
doi: 10.1158/1055-9965.EPI-10-1198. Epub. 2011 Mar 29.
18 Randazzo M et al., Is further screening of men with baseline PSA < 1 ng ml(-1) worthwhile? The discussion continues-Results of the Swiss ERSPC (Aarau). Int J Cancer. 2015 Aug 1;137(3):553-9.
doi: 10.1002/ijc.29420. Epub 2015 Jan 23.